Stockreport

Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF Kymera Therapeutics started dosing patients in its BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader, in moderate to severe eosinophilic asthma. KT-621 is also [Read more]